FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jorge Cortes

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Physiology

Drug Resistance, Neoplasm

Co-author Network

Publications

TOP 3
Wenli Zheng; Jorge E Cortes; Ying Hu; Hagop H Kantarjian; L Jeffrey Medeiros; Linda Powers; Farhad Ravandi-Kashani; Sa A Wang
CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes.
Michael S Mathisen; Farhad Ravandi; Gautam Borthakur; Jorge E Cortes; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Hagop Kantarjian; Alfonso Quintás-Cardama
Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Elias Jabbour; Susan O'Brien; Farhad Ravandi; William Wierda; Jorge E Cortes; Stefan Faderl; Amber Fullmer; Guillermo Garcia-Manero; Hagop Kantarjian
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jorge Cortes (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Wenli Zheng; Jorge E Cortes; Ying Hu; Hagop H Kantarjian; L Jeffrey Medeiros; Linda Powers; Farhad Ravandi-Kashani; Sa A Wang
CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes.
Clinical lymphoma, myeloma & leukemia 2013;13(3):307-14.
2013: Michael S Mathisen; Farhad Ravandi; Gautam Borthakur; Jorge E Cortes; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Hagop Kantarjian; Alfonso Quintás-Cardama
Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Clinical lymphoma, myeloma & leukemia 2013;13(2):139-43.
2013: Elias Jabbour; Susan O'Brien; Farhad Ravandi; William Wierda; Jorge E Cortes; Stefan Faderl; Amber Fullmer; Guillermo Garcia-Manero; Hagop Kantarjian
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
Clinical lymphoma, myeloma & leukemia 2013;13(2):131-8.
2012: Daniela Hoehn; Hagop M Kantarjian; L Jeffrey Medeiros; Xuemei Wang; Jorge E Cortes; Carlos E Bueso-Ramos
Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia.
Human pathology 2012;43(12):2354-9.
2012: Gautam Borthakur; Stefan Faderl; Tapan Kadia; Hagop Kantarjian; Rajyalakshmi Luthra; Keyur P Patel; Sherry Pierce; Wei Qiao; Farhad Ravandi; Jorge E Cortes
Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia.
Cancer 2012;118(23):5819-22.
2012: Jorge E Cortes; Michael W N Deininger; Brian J Druker; Ian W Flinn; Frank G Haluska; Simin Hu; Hagop Kantarjian; Michael J Mauro; Narayana I Narasimhan; Thomas O'Hare; Victor M Rivera; Neil P Shah; Dale Bixby; Tim Clackson; Christopher D Turner; Moshe Talpaz
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
The New England journal of medicine 2012;367(22):2075-88.
2012: Jorge E Cortes; Athena Countouriotis; Irina Dyagil; Karïn Gogat; Laimonas Griskevicius; Hagop M Kantarjian; Dong-Wook Kim; Hemant Malhotra; Christine Powell; Tim H Brümmendorf; Carlo Gambacorti-Passerini
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(28):3486-92.
2012: Srdan Verstovsek; Sherry Pierce; Ester Pungolino; Elisa Rumi; Deborah A Thomas; Gautam Borthakur; Domenica Caramazza; Mario Cazzola; Jorge E Cortes; Zeev Estrov; Elias Jabbour; Tapan Kadia; Hagop M Kantarjian; Enrica Morra; Francesco Passamonti
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Blood 2012;120(6):1202-9.
2012: Rajesh R Singh; Ashish Bains; Bedia A Barkoh; Tigist Bisrat; Jorge E Cortes; Hagop M Kantarjian; L Jeffrey Medeiros; Abhaya Paladugu; Keyur P Patel; Hamed Rahimi; Farhad Ravandi-Kashani; Rajyalakshmi Luthra
Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis.
The Journal of molecular diagnostics : JMD 2012;14(4):336-45.
2012: Guillermo Garcia-Manero; Yumin Hu; Elias Jabbour; Tapan M Kadia; Nebiyou B Bekele; Gautam Borthakur; Mark Brandt; Jorge E Cortes; Marcos de Lima; Stefan Faderl; Marina Y Konopleva; Deborah McCue; Willie Mae Newsome; Sherry R Pierce; Farhad Ravandi; Francesco Paolo Tambaro; Hui Yang; Hagop M Kantarjian
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(18):2204-10.
2012: Hagop M Kantarjian; Dong-Wook Kim; Jorge H Milone; Franck E Nicolini; Michinori Ogura; Carolina Pavlovsky; Tadeusz Robak; Neil P Shah; María Soledad Undurraga; Jan Van Droogenbroeck; Edo Vellenga; Jianxiang Wang; Chao Zhu; Juan Julio Kassack Ipiña; Mohan B Agarwal; Michele Baccarani; M Brigid Bradley-Garelik; Jorge E Cortes; Christian Junghanss; Andreas Hochhaus
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Blood 2012;119(5):1123-9.
2012: Maria Cabanillas; B Nebiyou Bekele; Eduardo Bruera; Maria C Foudray; Hagop Kantarjian; Gloria N Mattiuzzi; Michael E Rytting; Deborah A Thomas; Lianchun Xiao; Jorge E Cortes
Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial.
Cancer 2012;118(3):848-55.
2012: Jorge E Cortes
Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(3):223-4.
2011: Elias Jabbour; Hagop M Kantarjian; Susan O'Brien; Alfonso Quintás-Cardama; Mary Beth Rios; Jianqin Shan; Guillermo Garcia-Manero; Jorge E Cortes
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(32):4260-5.
2011: Jorge E Cortes; Richat Abbas; Steven Arkin; Nadine Besson; Tim H Brümmendorf; Hagop M Kantarjian; H Jean Khoury; Dong-Wook Kim; Eric Leip; Ricardo Pasquini; Zhi-Xiang Shen; Anna G Turkina; Angela Volkert; Junyuan Wang; Carlo Gambacorti-Passerini
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Blood 2011;118(17):4567-76.
2011: Lisa S Chen; Jorge E Cortes; Sanjeev Redkar; Pietro Taverna; Varsha Gandhi
Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
Blood 2011;118(3):693-702.
2011: Jorge E Cortes; Andreas Hochhaus; Philipp D le Coutre; Gianantonio Rosti; Javier Pinilla-Ibarz; Elias Jabbour; Kathryn Gillis; Richard C Woodman; Rick E Blakesley; Francis J Giles; Hagop M Kantarjian; Michele Baccarani
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.
Blood 2011;117(21):5600-6.
2011: Fabio P S Santos; Dan Jones; Wei Qiao; Jorge E Cortes; Farhad Ravandi; Elihu E Estey; Dushyant Verma; Hagop Kantarjian; Gautam Borthakur
Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.
Cancer 2011;117(10):2145-55.
2011: Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E Cortes; Hagop M Kantarjian
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Cancer 2011;117(9):1800-11.
2011: Katja Karjalainen; Diana E Jaalouk; Carlos E Bueso-Ramos; Amado J Zurita; Akihiko Kuniyasu; Bedrich Eckhardt; Frank C Marini; Benjamin Lichtiger; Susan O'Brien; Hagop M Kantarjian; Jorge E Cortes; Erkki Koivunen; Wadih Arap; Renata Pasqualini
Targeting neuropilin-1 in human leukemia and lymphoma.
Blood 2011;117(3):920-7.
2010: Gloria N Mattiuzzi; Jorge E Cortes; Deborah A Blamble; B Nebiyou Bekele; Lianchun Xiao; Maria Cabanillas; Gautam Borthakur; Susan O'Brien; Hagop Kantarjian
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
Cancer 2010;116(24):5659-66.
2010: Amit Lahoti; Andrew Lamb; Abdulla K Salahudeen; Farhad Ravandi; Jorge E Cortes; Stefan Faderl; Susan O'Brien; William G Wierda; Gloria N Mattiuzzi
Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.
Cancer 2010;116(17):4063-8.
2010: Stefan Faderl; Guillermo Garcia-Manero; Zeev Estrov; Farhad Ravandi; Gautam Borthakur; Jorge E Cortes; Susan O'Brien; Varsha Gandhi; William Plunkett; Anna Byrd; Monica Kwari; Hagop M Kantarjian
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(16):2755-60.
2010: Ping Shi; Joya Chandra; Xiaoping Sun; Mate Gergely; Jorge E Cortes; Guillermo Garcia-Manero; Ralph B Arlinghaus; Raymond Lai; Hesham M Amin
Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells.
Journal of cellular and molecular medicine 2010;14(6B):1777-92.
2010: Farshid Dayyani; Anthony P Conley; Sara S Strom; William Stevenson; Jorge E Cortes; Gautam Borthakur; Stefan Faderl; Susan O'Brien; Sherry Pierce; Andrew Lamb; Guillermo Garcia-Manero
Cause of death in patients with lower-risk myelodysplastic syndrome.
Cancer 2010;116(9):2174-9.
2010: Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith William Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(11):1856-62.
2010: Jan A Burger; N S Velev; Elias Jabbour; William G Wierda; Farhad Ravandi; Jorge E Cortes; Andrew Lamb; Y L Nieto; Elizabeth J Shpall; Jeffrey L Jorgensen
Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells.
Leukemia 2010;24(3):666-8.
2010: Sameer A Parikh; Hagop M Kantarjian; Mary Ann Richie; Jorge E Cortes; Srdan Verstovsek
Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis.
Leukemia & lymphoma 2010;51(2):269-74.
2010: Jorge E Cortes; Michele Baccarani; François Guilhot; Brian J Druker; Susan Branford; Dong-Wook Kim; Fabrizio Pane; Ricardo Pasquini; Stuart L Goldberg; Matt Kalaycio; Beatriz Moiraghi; Jacob M Rowe; Elena Tothova; Carmino De Souza; Marc Rudoltz; Richard Yu; Tillmann Krahnke; Hagop M Kantarjian; Jerald P Radich; Timothy P Hughes
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(3):424-30.
2010: Jorge E Cortes; Dan Jones; Susan O'Brien; Elias Jabbour; Marina Konopleva; Alessandra Ferrajoli; Tapan Kadia; Gautam Borthakur; Denise Stigliano; Jianqin Shan; Andrew Lamb
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(3):392-7.
2010: Jorge E Cortes; Dan Jones; Susan O'Brien; Elias Jabbour; Farhad Ravandi; Charles Koller; Gautam Borthakur; Brenda Walker; Weiqiang Zhao; Jianqin Shan; Andrew Lamb
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(3):398-404.
2010: Nikolay D Dimov; L Jeffrey Medeiros; Hagop M Kantarjian; Jorge E Cortes; Kun-Sang Chang; Carlos E Bueso-Ramos; Farhad Ravandi
Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients.
Cancer 2010;116(2):369-76.
2009: Arturo Vega-Ruiz; Jorge E Cortes; Matjaz Sever; Taghi Manshouri; Alfonso Quintás-Cardama; Rajyalakshmi Luthra; Hagop M Kantarjian; Srdan Verstovsek
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
Leukemia research 2009;33(11):1481-4.
2009: Jorge E Cortes; Hagop M Kantarjian; Stuart L Goldberg; Bayard L Powell; Francis Giles; Meir Wetzler; Luke Akard; John M Burke; Robert Kerr; Mansoor Saleh; August Salvado; Karen McDougall; Maher Albitar; Jerald P Radich
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4754-9.
2009: Jorge E Cortes; M J Egorin; françois guilhot; mathieu molimard; F-X Mahon
Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia.
Leukemia 2009;23(9):1537-44.
2009: Gautam Borthakur; Edward Lin; Nitin Jain; Elihu E Estey; Jorge E Cortes; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Sherry Pierce; Andrew Lamb
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
Cancer 2009;115(14):3217-21.
2009: C Cameron Yin; Lynne V Abruzzo; Xiaoyan Qiu; Effrosyni Apostolidou; Jorge E Cortes; L Jeffrey Medeiros; Gary Lu
del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia.
Cancer genetics and cytogenetics 2009;192(1):18-23.
2009: Alfonso Quintás-Cardama; Jorge E Cortes; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; David Liu; Eric Bleickardt; Tai-Tsang Chen; Hagop M Kantarjian
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Cancer 2009;115(13):2912-21.
2009: Alfonso Quintás-Cardama; Hagop M Kantarjian; Jorge E Cortes
Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.
Cancer control : journal of the Moffitt Cancer Center 2009;16(2):122-31.
2009: Elias Jabbour; Jorge E Cortes; Hagop M Kantarjian
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
Mayo Clinic proceedings. Mayo Clinic 2009;84(2):161-9.
2009: Srdan Verstovsek; Ayalew Tefferi; Andrew Lamb; Taghi Manshouri; Raja Luthra; Animesh Pardanani; Alfonso Quintás-Cardama; Farhad Ravandi; Patricia Ault; Carlos Bueso-Ramos; Jorge E Cortes
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):368-73.
2008: Dan Jones; Deborah Thomas; C Cameron Yin; Susan O'Brien; Jorge E Cortes; Elias Jabbour; Megan Breeden; Francis Giles; Weiqiang Zhao; Hagop M Kantarjian
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Cancer 2008;113(5):985-94.
2008: Taghi Manshouri; Alfonso Quintás-Cardama; Roberto H Nussenzveig; Amos Gaikwad; Zeev Estrov; Josef T Prchal; Jorge E Cortes; Hagop M Kantarjian; Srdan Verstovsek
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Cancer science 2008;99(6):1265-73.
2008: Elias Jabbour; Jorge E Cortes; Hagop M Kantarjian
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.
Cancer 2008;112(10):2112-8.
2008: Razelle Kurzrock; Hagop M Kantarjian; Michelle A Blascovich; Cindy Bucher; Srdan Verstovsek; John J Wright; Susan R Pilat; Jorge E Cortes; Elihu H Estey; Francis Giles; Miloslav Beran; Said M Sebti
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):509-14.
2008: Elias Jabbour; Jorge E Cortes; Hady Ghanem; Susan O'Brien; Hagop M Kantarjian
Targeted therapy in chronic myeloid leukemia.
Expert review of anticancer therapy 2008;8(1):99-110.
2007: Francis Giles; Alan F List; Michael Carroll; Jorge E Cortes; Joyce Valickas; Bee-Lian Chen; Eric Masson; Christian Jacques; Dirk Laurent; Maher Albitar; Eric J Feldman; Gail J Roboz
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
Leukemia research 2007;31(7):891-7.
2007: Elias Jabbour; Jorge E Cortes; Francis Giles; Susan O'Brien; Hagop M Kantarjian
Current and emerging treatment options in chronic myeloid leukemia.
Cancer 2007;109(11):2171-81.
2007: Ahmed Aribi; Hagop M Kantarjian; Elihu H Estey; Charles Koller; Deborah A Thomas; Steven M Kornblau; Stefan Faderl; Nakia M Laddie; Guillermo Garcia-Manero; Jorge E Cortes
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Cancer 2007;109(7):1355-9.
2007: Gautam Borthakur; Susan O'Brien; William G Wierda; Deborah A Thomas; Jorge E Cortes; Francis Giles; Hagop M Kantarjian; Susan Lerner; Michael J Keating
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
British journal of haematology 2007;136(6):800-5.
2007: Ricardo H Alvarez; Andrew Lamb; Jorge E Cortes
The biology of chronic myelogenous leukemia: implications for imatinib therapy.
Seminars in hematology 2007;44(1 Suppl 1):S4-14.
2007: Jingxuan Pan; Alfonso Quintás-Cardama; Hagop M Kantarjian; Cem Akin; Taghi Manshouri; Peter Lamb; Jorge E Cortes; Ayalew Tefferi; Francis Giles; Srdan Verstovsek
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Blood 2007;109(1):315-22.
2006: Ricardo H Alvarez; Hagop M Kantarjian; Jorge E Cortes
The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors.
Cancer 2006;107(8):1918-29.
2006: Ricardo H Alvarez; Hagop M Kantarjian; Jorge E Cortes
Biology of platelet-derived growth factor and its involvement in disease.
Mayo Clinic proceedings. Mayo Clinic 2006;81(9):1241-57.
2006: Alfonso Quintás-Cardama; Jorge E Cortes
Chronic myeloid leukemia: diagnosis and treatment.
Mayo Clinic proceedings. Mayo Clinic 2006;81(7):973-88.
2006: Gail J Roboz; Francis Giles; Alan F List; Jorge E Cortes; R Carlin; M Kowalski; S Bilic; Eric Masson; M Rosamilia; Michael W Schuster; D Laurent; Eric J Feldman
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Leukemia 2006;20(6):952-7.
2006: Deborah A Thomas; Francis Giles; Maher Albitar; Jorge E Cortes; Srdan Verstovsek; Stefan Faderl; Susan M O'Brien; Guillermo Garcia-Manero; Michael J Keating; Sherry Pierce; Jerome B Zeldis; Hagop M Kantarjian
Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Cancer 2006;106(9):1974-84.
2006: Jorge E Cortes; Moshe Talpaz; Susan O'Brien; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; Srdan Verstovsek; Mary Beth Rios; Jianqin Shan; Hagop M Kantarjian
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Cancer 2006;106(6):1306-15.
2005: Francis Giles; Jorge E Cortes; Hagop M Kantarjian
Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
Current molecular medicine 2005;5(7):615-23.
2005: H Gao; Bang-Ning Lee; Moshe Talpaz; Nicholas J Donato; Jorge E Cortes; Hagop M Kantarjian; James M Reuben
Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia.
Leukemia 2005;19(11):1905-11.
2005: Francis Giles; Hagop M Kantarjian; Jorge E Cortes; Stefan Faderl; Srdan Verstovsek; Deborah Thomas; Guillermo Garcia-Manero; William G Wierda; Alessandra Ferrajoli; Steven M Kornblau; Gloria N Mattiuzzi; Apostolia-Maria Tsimberidou; Maher Albitar; Susan M O'Brien; Elihu Estey
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Leukemia research 2005;29(6):649-52.
2004: Hagop M Kantarjian; Jorge E Cortes; Susan O'Brien; Rajyalakshmi Luthra; Francis Giles; Srdan Verstovsek; Stefan Faderl; Deborah Thomas; Guillermo Garcia-Manero; Mary Beth Rios; Jianqin Shan; Dan Jones; Moshe Talpaz
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
Blood 2004;104(7):1979-88.
2004: Francis Giles; Jorge E Cortes; Hagop M Kantarjian; Susan M O'Brien
Accelerated and blastic phases of chronic myelogenous leukemia.
Hematology/oncology clinics of North America 2004;18(3):753-74, xii.
2004: Jorge E Cortes; Susan M O'Brien; Francis Giles; Ricardo H Alvarez; Moshe Talpaz; Hagop M Kantarjian
Investigational strategies in chronic myelogenous leukemia.
Hematology/oncology clinics of North America 2004;18(3):619-39, ix.
2004: Gautam Borthakur; Jorge E Cortes
Imatinib mesylate in the treatment of chronic myelogenous leukemia.
International journal of hematology 2004;79(5):411-9.
2004: Francis Giles; Jorge E Cortes; Hagop M Kantarjian; Susan M O'Brien; Elihu Estey; Miloslav Beran
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Leukemia research 2004;28(4):353-7.
2004: Razelle Kurzrock; Maher Albitar; Jorge E Cortes; Elihu H Estey; Stefan Faderl; Guillermo Garcia-Manero; Deborah A Thomas; Francis Giles; Mary Ellen Ryback; Alain Thibault; P De Porre; Hagop M Kantarjian
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(7):1287-92.
2004: Francis Giles; Martin S Tallman; Guillermo Garcia-Manero; Jorge E Cortes; Deborah A Thomas; William G Wierda; Srdan Verstovsek; Marta Hamilton; Emma Barrett; Maher Albitar; Hagop M Kantarjian
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
Cancer 2004;100(7):1449-58.
2004: Thomas B Sneed; Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rios; B Nebiyou Bekele; Xian Zhou; Debra Resta; William G Wierda; Stefan Faderl; Francis Giles; Jorge E Cortes
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Cancer 2004;100(1):116-21.
2003: Apostolia-Maria Tsimberidou; Elihu Estey; Jorge E Cortes; Guillermo Garcia-Manero; Stefan Faderl; Srdan Verstovsek; Deborah A Thomas; Alessandra Ferrajoli; Michael J Keating; Susan O'Brien; Hagop M Kantarjian; Francis Giles
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Cancer chemotherapy and pharmacology 2003;52(6):449-52.
2003: Francis Giles; Eric J Feldman; Gail J Roboz; Richard A Larson; Steven W Mamus; Jorge E Cortes; Srdan Verstovsek; Stefan Faderl; Moshe Talpaz; Miloslav Beran; Maher Albitar; Susan M O'Brien; Hagop M Kantarjian
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Leukemia research 2003;27(12):1091-6.
2003: Francis Giles; Paula M Fracasso; Hagop M Kantarjian; Jorge E Cortes; Randy A Brown; Srdan Verstovsek; Yesid Alvarado; Deborah A Thomas; Stefan Faderl; Guillermo Garcia-Manero; Lisa P Wright; Tom Samson; Ann Cahill; Paula Lambert; William Plunkett; Mario Sznol; John F DiPersio; Varsha Gandhi
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Leukemia research 2003;27(12):1077-83.
2003: Francis Giles; Jorge E Cortes; Terri A Halliburton; Susie J Mallard; Elihu H Estey; Tracey A Waddelow; JoAnn T Lim
Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions.
The Annals of pharmacotherapy 2003;37(9):1182-5.
2003: Apostolia-Maria Tsimberidou; Dawn E Colburn; Mary Alma Welch; Jorge E Cortes; Srdan Verstovsek; Susan M O'Brien; Maher Albitar; Hagop M Kantarjian; Francis Giles
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
Cancer chemotherapy and pharmacology 2003;52(3):229-34.
2003: Francis Giles; Gary Guangping Shi; Jorge E Cortes; Deborah Thomas; Anna R Keating; Hagop M Kantarjian; Michael J Keating; Susan M O'Brien
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.
Cancer chemotherapy and pharmacology 2003;52(3):223-8.
2003: Hesham M Amin; Iman Jilani; Elihu H Estey; Michael J Keating; Amanda L Dey; Taghi Manshouri; Hagop M Kantarjian; Zeev Estrov; Jorge E Cortes; Deborah A Thomas; Francis Giles; Maher Albitar
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome.
Blood 2003;102(5):1866-8.
2003: Alessandra Ferrajoli; Susan M O'Brien; Jorge E Cortes; Francis Giles; Deborah A Thomas; Stefan Faderl; Razelle Kurzrock; Susan Lerner; Dimitrios P Kontoyiannis; Michael J Keating
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
Cancer 2003;98(4):773-8.
2003: Francis Giles; Alison T Stopeck; Lewis R Silverman; Jeffrey E Lancet; Maureen A Cooper; Alison L Hannah; Julie M Cherrington; Anne-Marie O'Farrell; Helene A Yuen; Sharianne G Louie; Weiru Hong; Jorge E Cortes; Srdan Verstovsek; Maher Albitar; Susan M O'Brien; Hagop M Kantarjian; Judith E Karp
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Blood 2003;102(3):795-801.
2003: Marina Konopleva; Su-Chun Cheng; Jorge E Cortes; Kimberly J Hayes; Sherry A Pierce; Michael Andreeff; Francis Giles; Susan O'Brien; Hagop M Kantarjian; Elihu H Estey
Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.
Haematologica 2003;88(7):733-6.
2003: Apostolia-Maria Tsimberidou; Hagop M Kantarjian; Elihu Estey; Jorge E Cortes; Srdan Verstovsek; Stefan Faderl; D A Thomas; Guillermo Garcia-Manero; Alessandra Ferrajoli; John T Manning; Michael J Keating; Maher Albitar; Susan O'Brien; Francis Giles
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
Leukemia 2003;17(6):1100-3.
2003: Jorge E Cortes; Moshe Talpaz; Francis Giles; Susan O'Brien; Mary Beth Rios; Jianqin Shan; Guillermo Garcia-Manero; Stefan Faderl; Deborah A Thomas; William G Wierda; Alessandra Ferrajoli; Sima Jeha; Hagop M Kantarjian
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Blood 2003;101(10):3794-800.
2003: Francis Giles; B Nebiyou Bekele; Susan O'Brien; Jorge E Cortes; Srdan Verstovsek; Maria Balerdi; Marwan Yared; Xian Zhou; Hagop M Kantarjian; Michael J Keating; Peter F Thall; Maher Albitar
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression.
British journal of haematology 2003;121(4):578-85.
2003: Francis Giles; Hagop M Kantarjian; Jorge E Cortes; Guillermo Garcia-Manero; Srdan Verstovsek; Stefan Faderl; Deborah A Thomas; Alessandra Ferrajoli; Susan O'Brien; J Kyle Wathen; Lian-Chun Xiao; Donald A Berry; Elihu H Estey
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1722-7.
2003: Francis Giles; Stefan Faderl; Deborah A Thomas; Jorge E Cortes; Guillermo Garcia-Manero; Dan Douer; Alexandra M Levine; Charles Koller; Sima Jeha; Susan M O'Brien; Elihu H Estey; Hagop M Kantarjian
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1050-6.
2003: Gloria N Mattiuzzi; Jorge E Cortes; Moshe Talpaz; James M Reuben; Mary Beth Rios; Jianjin Shan; Dimitrios P Kontoyiannis; Francis Giles; Issam Raad; Srdan Verstovsek; Alessandra Ferrajoli; Hagop M Kantarjian
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(3):976-80.
2003: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Jianqin Shan; Francis Giles; Mary Beth Rios; Stefan Faderl; William G Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Michael J Keating; Emil J Freireich; Moshe Talpaz
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Cancer 2003;97(4):1033-41.
2003: Hagop M Kantarjian; Jorge E Cortes; Susan O'Brien; Francis Giles; Guillermo Garcia-Manero; Stefan Faderl; Deborah Thomas; Sima Jeha; Mary Beth Rios; Laurie Letvak; Kathy Bochinski; Ralph B Arlinghaus; Moshe Talpaz
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
Blood 2003;101(1):97-100.
2002: Francis Giles; Hagop M Kantarjian; B Nebiyou Bekele; Jorge E Cortes; Stefan Faderl; Deborah A Thomas; Taghi Manshouri; Anna Rogers; Michael J Keating; Moshe Talpaz; Susan O'Brien; Maher Albitar
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival.
British journal of haematology 2002;119(1):38-45.
2002: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Sergio Giralt; Mary Beth Rios; Jianqin Shan; Francis Giles; Deborah A Thomas; Stefan Faderl; Marcos De Lima; Guillermo Garcia-Manero; Richard Champlin; Ralph B Arlinghaus; Moshe Talpaz
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Blood 2002;100(5):1590-5.
2002: Hagop M Kantarjian; Jorge E Cortes; Jacob M Rowe; Razelle Kurzrock
Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies.
Seminars in hematology 2002;39(3 Suppl 2):36-8.
2002: Jorge E Cortes; Razelle Kurzrock; Hagop M Kantarjian
Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies.
Seminars in hematology 2002;39(3 Suppl 2):26-30.
2002: Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Terry L Smith; Francis Giles; Stefan Faderl; Deborah A Thomas; Guillermo Garcia-Manero; Jean-Pierre J Issa; Michael Andreeff; Steven M Kornblau; Charles Koller; Miloslav Beran; Michael Keating; Mary Beth Rios; Jianqin Shan; Debra Resta; Renaud Capdeville; Kimberly Hayes; Maher Albitar; Emil J Freireich; Jorge E Cortes
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2177-87.
2002: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Terry L Smith; Mary Beth Rios; Jianqin Shan; Ying Yang; Francis Giles; Deborah A Thomas; Stefan Faderl; Guillermo Garcia-Manero; Sima Jeha; William G Wierda; Jean-Pierre J Issa; Steven M Kornblau; Michael Keating; Debra Resta; Renaud Capdeville; Moshe Talpaz
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2167-76.
2002: Francis Giles; Jorge E Cortes; Deborah A Thomas; Guillermo Garcia-Manero; Stefan Faderl; Sima Jeha; Robert L De Jager; Hagop M Kantarjian
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2134-41.
2002: Elihu H Estey; Peter F Thall; Francis Giles; Xue-Mei Wang; Jorge E Cortes; Miloslav Beran; Sherry A Pierce; Deborah A Thomas; Hagop M Kantarjian
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Blood 2002;99(12):4343-9.
2002: Yesid Alvarado; Hagop M Kantarjian; Jorge E Cortes; Effrosyni Apostolidou; Carol Bivins; Francis Giles
Troxacitabine activity in extramedullary myeloid leukemia.
Hematology (Amsterdam, Netherlands) 2002;7(3):179-85.
2002: Elihu H Estey; Francis Giles; Miloslav Beran; Susan O'Brien; Sherry A Pierce; Stefan Faderl; Jorge E Cortes; Hagop M Kantarjian
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.
Blood 2002;99(11):4222-4.
2002: Apostolia-Maria Tsimberidou; Susan M O'Brien; Jorge E Cortes; Stefan Faderl; Michael Andreeff; Hagop M Kantarjian; Michael J Keating; Francis Giles
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
Leukemia & lymphoma 2002;43(4):767-72.
2002: Yuk Fung Hui; Francis Giles; Jorge E Cortes
Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome--recall following different chemotherapy agents.
Investigational new drugs 2002;20(1):49-53.
2002: Usha R Surapaneni; Jorge E Cortes; Deborah Thomas; Susan O'Brien; Francis Giles; Charles Koller; Stefan Faderl; Andrew Lamb
Central nervous system relapse in adults with acute lymphoblastic leukemia.
Cancer 2002;94(3):773-9.
2002: Francis Giles; Guillermo Garcia-Manero; Jorge E Cortes; Sharyn D Baker; Carole B Miller; Susan M O'Brien; Deborah A Thomas; Michael Andreeff; Carol Bivins; Jacques Jolivet; Hagop M Kantarjian
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):656-64.
2001: Elihu H Estey; Peter F Thall; Jorge E Cortes; Francis Giles; Susan O'Brien; Sherry A Pierce; Xuemei Wang; Hagop M Kantarjian; Miloslav Beran
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Blood 2001;98(13):3575-83.
2001: Bouthaina S Dabaja; Susan M O'Brien; Hagop M Kantarjian; Jorge E Cortes; Deborah A Thomas; Maher Albitar; E S Schlette; Stefan Faderl; Andreas H Sarris; Michael J Keating; Francis Giles
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome.
Leukemia & lymphoma 2001;42(3):329-37.
2001: Francis Giles; Jorge E Cortes; Sharyn D Baker; Deborah A Thomas; Susan O'Brien; Terry L Smith; Miloslav Beran; Carol Bivins; J Jolivet; Hagop M Kantarjian
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):762-71.
2000: Yuk Fung Hui; Jorge E Cortes
Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin.
Pharmacotherapy 2000;20(10):1221-3.
2000: Moshe Talpaz; X Qiu; Keding Cheng; Jorge E Cortes; Andrew Lamb; Razelle Kurzrock
Autoantibodies to Abl and Bcr proteins.
Leukemia 2000;14(9):1661-6.
2000: Yuk Fung Hui; Jorge E Cortes
Chest and back pain associated with a six-hour infusion of liposomal daunorubicin.
The Annals of pharmacotherapy 2000;34(6):810-1.
1999: Jorge E Cortes; Hagop M Kantarjian; Susan O'Brien; Francis Giles; Michael J Keating; Emil J Freireich; Elihu H Estey
A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.
Cancer 1999;85(7):1506-13.
1999: Alvaro Aguayo; Jorge E Cortes; Hagop M Kantarjian; Miloslav Beran; Varsha Gandhi; William Plunkett; Joanne Kurtzberg; Michael J Keating
Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature.
Cancer 1999;85(1):58-64.
1997: EJ Rodriguez-Monge; Jorge E Cortes; Susan O'Brien; Moshe Talpaz; Hagop M Kantarjian
Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia.
Cancer 1997;80(3):396-400.